Literature DB >> 26086759

A Phase I/IIa Clinical Trial in Duchenne Muscular Dystrophy Using Systemically Delivered Morpholino Antisense Oligomer to Skip Exon 53 (SKIP-NMD).

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26086759     DOI: 10.1089/humc.2015.2528

Source DB:  PubMed          Journal:  Hum Gene Ther Clin Dev        ISSN: 2324-8637            Impact factor:   5.032


× No keyword cloud information.
  1 in total

Review 1.  Splice-switching antisense oligonucleotides as therapeutic drugs.

Authors:  Mallory A Havens; Michelle L Hastings
Journal:  Nucleic Acids Res       Date:  2016-06-10       Impact factor: 16.971

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.